Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of Vinexin-beta gene in coronary atherosclerotic heart disease

A technology for coronary atherosclerosis and heart disease, applied in the field of gene function and application

Active Publication Date: 2014-07-02
武汉惠康基因科技有限公司
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no international literature report on the application of Vinexin-β gene in coronary atherosclerotic heart disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Vinexin-beta gene in coronary atherosclerotic heart disease
  • Application of Vinexin-beta gene in coronary atherosclerotic heart disease
  • Application of Vinexin-beta gene in coronary atherosclerotic heart disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] [Example 1] Myocardial infarction (MI) model acquisition

[0042] 1. Grouping of experimental animals: male C57BL / 6 background mice (WT), Vinexin-β gene knockout mice (Vinexin-β-KO) and heart-specific Vinexin-β transgenic mice (Vinexin-β-TG) and In non-transgenic mice (NTG), the myocardial infarction (MI) model was induced by ligation of the left anterior descending coronary artery (LAD) of the mouse heart. They were randomly divided into 8 groups, each group: C57BL / 6 background WT mouse sham operation group (WT Sham) and MI operation group (WT MI), Vinexin-β gene knockout mouse sham operation group (Vinexin-β-KO Sham ) and MI operation group (Vinexin-β-KO MI), non-transgenic mouse sham operation group (NTG Sham) and MI operation group (NTG MI), heart-specific Vinexin-β transgenic mouse sham operation group (Vinexin-β -TG Sham) and MI group (Vinexin-β-TG MI).

[0043] 2. The MI model uses blocking the left anterior descending coronary artery (LAD) of the mouse heart t...

Embodiment 2

[0052] [Example 2] Mouse myocardial infarction (MI) model myocardial infarction ratio, myocardial hypertrophy and fibrosis detection

[0053] 1. Collect materials

[0054] (1) Preliminary work: prepare a urine cup filled with 20mL of 10% formaldehyde in advance, and label it (mouse number, group, type of operation and date of collection). Place the petri dish filled with 10% KCl solution at the sampling site. Turn on the analytical balance, adjust to zero, and then weigh and kill the mice.

[0055] (2) Material collection: Ophthalmic curved forceps clamped the vascular pedicle below the atrial appendage, cut off the heart, and quickly placed it in 10% KCl solution. After the heart stops beating in the diastolic phase, place it on sterilized gauze, gently squeeze the fluid in the heart cavity, dip the surface fluid dry, weigh and record, put the heart into the corresponding urine cup, fix it for 48 hours and use it for pathological testing.

[0056] (3) Relevant measurement...

Embodiment 3

[0073] [Example 3] Cardiac function detection in myocardial infarction (MI) model mice

[0074] 1 Ultrasound detection of cardiac function

[0075] 1.1 Preliminary preparation

[0076] (1) Anesthesia machine preparation: first connect the oxygen cylinder and the air inlet port on the anesthesia machine, then unscrew the sealing cap of the dosing port on the anesthesia machine, quickly add isoflurane to the safety scale, and then tighten the sealing cap. Unscrew the main valve on the oxygen cylinder, adjust the knob of the flow control valve, and maintain the outlet pressure at 0.2-0.3mPa.

[0077] (2) Preparation of the mice to be tested: After the mice to be tested were quickly anesthetized with isoflurane, the hair on the left chest area was shaved, and the head of the treated mice was inserted into the anesthetic catheter sleeve, and treated with 1.5-2.0% isoflurane Alkane maintains a stable anesthesia in mice.

[0078] 1.2 Cardiac function test

[0079] The mice were p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a Vinexin-beta gene in coronary atherosclerotic heart disease, and belongs to the field of functions and application of the gene. According to the invention, Vinexin-beta knockout mouse and heart specificity Vinexin-beta transgenic mouse serve as experimental subjects and mouse heart ramus descendens anterior arteriae coronariae sinistrae (LAD) is blocked to form a myocardial infarction model, and a result shows that, compared with a WT control mouse, the Vinexin-beta knockout mouse is significantly inhibited in myocardial infarction proportion, myocardial hypertrophy and fibrosis degree and is remarkably better in heart functions, while the heart specificity Vinexin-beta transgenic mouse is obviously more serious in myocardial infarction proportion, myocardial hypertrophy and fibrosis degree and is remarkably worse in the heart functions, showing that the Vinexin-beta gene can promote and enhance occurrence and development of the coronary atherosclerotic heart disease. Therefore, the Vinexin-beta gene can serve as a drug target to screen medicines for treating the coronary atherosclerotic heart disease, and a Vinexin-beta inhibitor can be used for preparing a medicine for treating the coronary atherosclerotic heart disease.

Description

technical field [0001] The invention belongs to the field of gene function and application, in particular to the function and application of Vinexin-β gene in coronary atherosclerotic heart disease. Background technique [0002] Cardiovascular disease is a common and frequently-occurring disease that seriously threatens human life and health, and is the number one killer of human health. Ischemic heart disease is the leading cause of death from cardiovascular diseases. Myocardial infarction (MI) is a common type of ischemic heart disease. If the blood supply of the myocardium is blocked for more than 30 minutes, various organelles will be ultrafine. Structural changes and dysfunction lead to irreversible damage and even death of cardiomyocytes. Within a few minutes after the onset of acute myocardial infarction, the myocardial cells in the ischemic central area will die due to ischemia, which is one of the common diseases that seriously threaten human health and life. In re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K48/00A61K39/395A61P9/10A61P9/00
Inventor 李红良万埝张艳蒋丁胜王丕晓
Owner 武汉惠康基因科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com